Clinical Management and Prognosis of Gynecological Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 30 July 2024 | Viewed by 3506
Special Issue Editor
Special Issue Information
Dear Colleagues,
Over the last decade, advances have been made in tumor profiling in gynecologic cancers through DNA sequencing. This is seen in various gynecologic cancers, including ovarian, uterine and cervical malignancies. Biomarker-based therapy progress varies among these tumor types, but improvements in either progression-free or overall survival outcomes have been made. In ovarian cancer, molecular signatures differ between traditionally used histologic classifications. The finding of defective homologous recombination in 50% of high-grade serous carcinomas has led to treatment with PARP inhibitors. Conversely, 80% of low-grade serous carcinomas has activated MAPK kinase pathways, with a smaller cohort being estrogen and progesterone receptor-positive. MEK inhibitors and hormonal agents are effective in these patients. A rapidly increasing number of women have been diagnosed with uterine cancer in the past two decades. Finding effective treatments for women with advanced and recurrent endometrial cancer is urgent. The TCGA molecular subtypes of endometrial cancer identify tumors in four categories. The finding of an ultra-mutated DNA polymerase epsilon (POLE) tumor in high-grade histology can help de-escalate the treatment strategy. In contrast, a high copy number (p53 mutation) would draw attention to the consideration of system therapy. In this Special Issue, translational and clinical research or reviews are invited, as this provides a direction for future research in gynecologic cancers.
Prof. Dr. Linus T. Chuang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
